Fondacioni Secid

Fondacioni Secid, a non-profit foundation headquartered in Tiranë, Albania, functions as a prime recipient of federal grants and as a sub-recipient on infectious-disease and public-health programs funded by the U.S. Department of Health and Human Services Centers for Disease Control and Prevention (CDC). The vendor operates exclusively in the federal grant space — no federal contracts — with work focused on infectious-disease surveillance, laboratory capacity building, and One Health coordination across Southeast Europe.

Fondacioni Secid's customer base is entirely CDC-anchored. All nine awards in the portfolio — five as prime recipient and four as sub-recipient — originate from the CDC, representing 100% of the vendor's federal activity. The organization holds a current five-year cooperative agreement awarded September 30, 2026, valued at $800,000 under CFDA 93.318 (Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security). The award runs from October 1, 2026, through September 29, 2031, and funds surveillance and response capacity for influenza, priority respiratory pathogens, and other infectious-disease threats in Southeast Europe through integration of existing surveillance systems and One Health approaches. The work scope includes strengthening sentinel surveillance laboratory and genomic capacity, enhancing data integration and reporting, coordinating One Health efforts, and advancing outbreak readiness across participating countries (Albania, Bulgaria, Macedonia, Montenegro, Kosovo, Serbia, and Bosnia & Herzegovina).

Fondacioni Secid also operates as a sub-recipient under The Task Force For Global Health, Inc., with three sub-grant awards dated April 2023, January 2024, and January 2025, performing regional influenza work and country-specific surveillance support across the same Southeast European footprint. Combined obligated dollars across all nine awards total $10.6 million. Award frequency has remained sparse — one award in 2021 and 2023, two in 2025 — with recent momentum driven by the new five-year cooperative agreement now underway.